Aimovig (erenumab-aooe) / Amgen, Novartis 
Welcome,         Profile    Billing    Logout  
 12 Diseases   17 Trials   17 Trials   2487 News 


«12345678910111213...2425»
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Journal, Real-world evidence:  Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. (Pubmed Central) -  Aug 26, 2022   
    This described analysis of migraine patients who used monoclonal antibodies presented one of the first Brazilian experiences with real-world patients. Our results may enlighten clinicians on the outcomes and ways of prescribing anti-CGRP antibodies.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Observational data, Journal:  Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine. (Pubmed Central) -  Aug 22, 2022   
    Registration studies and real life studies have shown excellent efficacy and extraordinary tolerability of these treatments. Little is known about the possible differences between the three treatments and this observational study was conducted with a view to comparing the efficacy, safety and impact that anti-CGRP monclonal antibodies have on additional parameters such as disability in social, family and work activities.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Journal:  Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. (Pubmed Central) -  Aug 22, 2022   
    Little is known about the possible differences between the three treatments and this observational study was conducted with a view to comparing the efficacy, safety and impact that anti-CGRP monclonal antibodies have on additional parameters such as disability in social, family and work activities. Monoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Journal:  Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention. (Pubmed Central) -  Aug 22, 2022   
    Monoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH. Non-responders seem to have different personality traits in comparison to responders, with a higher tendency toward depressed mood and difficulty to feel pleasure previously found in migraineurs vs. non-migraineurs: the more strict certain traits are, the more difficult to treat the migraine could be.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion:  Imaging the Migraine Brain Pre- and Post-Erenumab (clinicaltrials.gov) -  Aug 9, 2022   
    P4,  N=50, Completed, 
    No new safety signals were reported. Recruiting --> Completed
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Journal:  Efficiency of erenumab in neurologist's real practice (Pubmed Central) -  Aug 6, 2022   
    Understanding patient characteristics and treatment utilization patterns among patients prescribed both a CGRP mAb and novel acute medication may provide valuable insight regarding migraine treatment selection for healthcare decision makers. The effectiveness and safety of erenumab in the outpatient practice is shown.
  • ||||||||||  Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial initiation date, Trial primary completion date:  Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study (clinicaltrials.gov) -  Aug 3, 2022   
    P=N/A,  N=1500, Not yet recruiting, 
    It is crucial to recognize the relationship between the medication and the circumscribed exanthema occurring distant from the injection site. Initiation date: Jun 2022 --> Sep 2022 | Trial primary completion date: Jun 2025 --> Sep 2025
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Observational data, Retrospective data, Journal, HEOR:  Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States. (Pubmed Central) -  Jul 26, 2022   
    OBJECTIVE: To compare all-cause and migraine-related HCRU and direct health care costs in patients with migraine initiating CGRP mAbs, galcanezumab (GMB), vs standard-of-care (SOC) preventive treatments in the United States...Adults (aged ≥ 18 years) with 1 or more claims for CGRP mAb (GMB, erenumab, or fremanezumab) or SOC preventive treatment between May 1, 2018, and June 30, 2019, were included...Independent analyses were conducted by IBM Watson Health. Eli Lilly and Company and IBM Watson Health collaborated on designing the study and interpreting results.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Biomarker, Enrollment closed:  INTERROGATE: Biomarker and Genetic Predictors of Erenumab Treatment Response (clinicaltrials.gov) -  Jul 21, 2022   
    P4,  N=1406, Active, not recruiting, 
    This re-confirms the clinical trial data also for this highly selected group. Recruiting --> Active, not recruiting
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Anti-CGRP treatment in difficult-to-treat chronic migraine patients (A7) -  Jul 18, 2022 - Abstract #EAN2022EAN_2604;    
    Nearly 50% of patients documented a significant improvement from the first cycle. Moreover, Erenumab was as effective in difficult-to-treat patients as in those who only failed up to 5 prophylactic treatments.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Use of CGRP monoclonal antibodies and patient-reported improvement: Results from the OVERCOME (EU) study (A7) -  Jul 18, 2022 - Abstract #EAN2022EAN_2593;    
    This analysis assessed clinical and demographic characteristics in those who had ever used erenumab, fremanezumab or galcanezumab. Most respondents taking a CGRP mAb for the preventive treatment of migraine reported their migraine as better since starting the medication.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Patterns of use of monoclonal antibodies for the preventive treatment of migraine: Results from the OVERCOME (EU) study (A6) -  Jul 18, 2022 - Abstract #EAN2022EAN_2408;    
    Reasons for starting mAbs were multiple, including physician recommendation and patient efficacy expectations. The finding that recommendation from others was the most frequent reason for switching highlights the importance of the patient-physician relationship and family support in the management of migraine.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Anti-CGRP antibodies efficacy in Chronic Migraine: an italian tertiary center experience (A6) -  Jul 18, 2022 - Abstract #EAN2022EAN_2407;    
    Anti-CGRP mAbs showed optimal efficacy and safety in most patients. The three studied mAbs did not show significant differences in clinical response.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
    Could symptom severity predict the response to anti-CGRP monoclonal antibodies in migraine? (A8) -  Jul 18, 2022 - Abstract #EAN2022EAN_2401;    
    Among the clinical features, worsening with activities severity could be a predictor of response to anti-CGRP/r monoclonal antibodies. These therapies are effective showing frequent but mild AE in real clinical practice.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  Erenumab for Idiosyncratic Facial Pain (clinicaltrials.gov) -  Jun 28, 2022   
    P4,  N=66, Recruiting, 
    The systemic exposure in Chinese subjects in terms of AUC was 70% higher than that in White subjects as previously reported. Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Retrospective data, Journal:  Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions. (Pubmed Central) -  Jun 24, 2022   
    P2, P3
    Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 This pooled analysis showed that immunogenicity had no meaningful clinical impact on efficacy or safety of erenumab in patients with migraine.Clinical Trial Registration: ClinicalTrials.gov, NCT01952574; ClinicalTrials.gov, NCT02456740; Clinicaltrials.gov NCT02483585; Clinicaltrials.gov, NCT02174861; Clinicaltrials.gov, NCT02630459; Clinicaltrials.gov, NCT03812224.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
    Retrospective data, Journal:  Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study. (Pubmed Central) -  Jun 22, 2022   
    WHAT IS NEW AND CONCLUSIONS?: Altogether, these results support previous real-life studies regarding effectiveness and safety and provide an interesting insight in how these preventive therapies are also effective in patients diagnosed with difficult to treat migraine who have previously failed, at least, three different drug classes stablished by current neurology guidelines for migraine prevention. Moreover, these data may suggest that erenumab and galcanezumab are able to not only diminish frequency, but also migraine intensity, and that it should be also considered as an effectiveness measure in line with other authors suggestion.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Observational data, Retrospective data, Journal, Real-world evidence:  Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. (Pubmed Central) -  Jun 22, 2022   
    In this real-world study on erenumab use in the UAE, patients prescribed erenumab achieved clinically meaningful reductions in MHD and MSMD at all assessed time points. Erenumab was well tolerated with no new safety events.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=404, Recruiting, 
    Erenumab was well tolerated with no new safety events. Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> May 2027 | Initiation date: Apr 2022 --> Jul 2022 | Trial primary completion date: Dec 2026 --> May 2026
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment closed:  A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache (clinicaltrials.gov) -  Jun 21, 2022   
    P4,  N=620, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> May 2027 | Initiation date: Apr 2022 --> Jul 2022 | Trial primary completion date: Dec 2026 --> May 2026 Recruiting --> Active, not recruiting
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Review, Journal:  Erenumab for episodic migraine. (Pubmed Central) -  Jun 15, 2022   
    Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.
  • ||||||||||  Journal:  Therapies targeting CGRP signaling for medication overuse headache. (Pubmed Central) -  Jun 15, 2022   
    The available data indicate that anti-CGRP mAbs represent a good mechanism-based and disease-specific therapeutical option with for MOH as long as detoxification and additional nonpharmaceutical interventions are operated. Future research should focus on long-term-controlled trials in MOH populations exclusively.
  • ||||||||||  Journal:  Treatment of migraine with monoclonal antibodies. (Pubmed Central) -  Jun 11, 2022   
    It is essential to form multidisciplinary teams that can identify patients who will benefit from these therapies, conducting cost-effective treatments. The follow-up of these therapies in the coming years is paramount due to the lack of experience in the management of these drugs and the peculiarity of disease evolution in migraine patients.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Review, Journal:  Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. (Pubmed Central) -  Jun 8, 2022   
    Among adult patients with chronic migraine and previous failure of medications for migraine prevention, erenumab was found to be effective and well-tolerated. Anti-CGRP or anti-CGRP receptor monoclonal antibodies are a promising preventive migraine therapy which can be particularly useful for resistant chronic migraine patients.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine (clinicaltrials.gov) -  Jun 2, 2022   
    P4,  N=322, Recruiting, 
    Future studies are needed to better understand the mutual influence between migraine and sleep disorders. Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Sep 2023